Disclosed are quinoline compounds of formula (I), wherein the substituents are as defined within the specification and R has the formula (R) as depicted. Examples of disclosed compounds include: 8-(hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl)-3-(phenylsulfonyl)quinoline benzyl 6-(3-(phenylsulfonyl)quinolin-8-yl)-3,6-diazabicyclo[3.2.0]heptane-3-carboxylate and tert-butyl 2-(3-(phenylsulfonyl)quinolin-8-yl)hexahydro-1H-pyrrolo[3,4-c]pyridine-5(6H)-carboxylate. Further disclosed is a pharmaceutical composition comprising a compound of formula (I), and its use in the manufacture of a medicament for the treatment of diseases of the central nervous system, addiction diseases or obesity.
